See today's BioWorld
To read the full story, subscribe or sign in.

FDA puts Biomarin gene therapy trial on hold, following expert discussion on safety

Sep. 7, 2021
By Richard Staines
The FDA has put a hold on a clinical study of a rare disease gene therapy BMN-307 from Biomarin Pharmaceutical Inc. after several mice developed liver tumors following a high dose in a preclinical trial.
BioWorld Regulatory Endocrine/metabolic Gene therapy FDA